Anonymous ID: d423c0 Jan. 23, 2025, 12:20 p.m. No.22420104   🗄️.is 🔗kun

>>22419918

 

Using mRNA as a therapeutic toolwas first proposed in the early 1990s and became feasible in the early 2000s. The first clinical trial of an mRNA vaccine was conducted in 2008 to treat prostate cancer.That vaccine was developed to stimulate the patient's immune system to attack prostate cancer cells. The results of that trial were promising and paved the way for further research in mRNA vaccines.

 

In 2013, the first mRNA vaccine was approved for use in humans. Provenge was designed to treat prostate cancer by using the patient's immune cells to attack cancer cells. This vaccine demonstrated the potential of mRNA technology to improve the immune system.

 

The development of mRNA vaccines for infectious diseases began in the early 2010s. In 2013, researchers at the University of Pennsylvania and the National Institutes of Health developed an mRNA vaccine for the Middle East Respiratory Syndrome (MERS) virus. That vaccine successfully treated the virus in animals and opened the doors to new advancements towards strengthening immunity.

 

However, the breakthrough moment for mRNA vaccines came in late 2019 with the emergence of the COVID-19 pandemic. Two of these vaccines — from Pfizer-BioNTech and Moderna — were approved for emergency use in the USA in December 2020. Today, millions of people worldwide have received mRNA vaccines as these have proven to be highly effective in preventing COVID-19 infections and reducing the severity of the disease.

 

Who invented the mRNA vaccine?

The development of mRNA vaccines is the result of decades of research that began at the University of Wisconsin in the 1990s. The recent COVID-19 mRNA vaccines, such as Pfizer-BioNTech and Moderna, were an outgrowth of that research and were developed by two teams of researchers who were able to develop those vaccines and see them approved for use within a specific period of time.

 

The Pfizer-BioNTech vaccine was developed by a team of researchers led by Dr. Ugur Sahin, CEO of BioNTech and Dr. Özlem Türeci, chief medical officer of the company. The two co-founded BioNTech in 2008 to use mRNA technology for cancer therapies.

 

Their research on cancer immunotherapy led to the discovery that mRNA could produce a specific protein that could stimulate the immune system to attack cancer cells. That discovery facilitated the development of the Pfizer-BioNTech COVID-19 vaccine.

 

In contrast, the Moderna vaccine was developed by a team of researchers led by Dr. Derrick Rossi and Dr. Noubar Afeyan, co-founders of Moderna. Dr Rossi was studying how to reprogram human cells to act like embryonic stem cells. That research led to the development of Moderna's mRNA technology platform that allowed the company to quickly develop a COVID-19.

 

Early research

Researchers at the University of Wisconsin in the 1990s introduced the idea of using mRNA as a vaccination tool. The initial stage of the research focused on using mRNA to stimulate the immune system to respond against cancer cells. Researchers began exploring the use of mRNA for infectious diseases, such as influenza and Zika virus, in the early 2000s.

 

An important milestone in the research involves the development of a self-amplifying mRNA vaccine platform in 2012 by researchers at Imperial College London. After that, in 2013, Moderna began a Phase 1 clinical trial for a personalized cancer vaccine that used mRNA technology.

 

What was the first mRNA vaccine?

Pfizer-BioNTech COVID-19 vaccine was the first mRNA vaccine to receive emergency use authorization from the FDA when it was approved for use in people 16 years and older in December 2020.

 

The Pfizer-BioNTech COVID-19 vaccine was developed to prevent COVID-19 due to the SARS-CoV-2 virus. It is a two-dose vaccine administered three weeks apart. The vaccine contains a small piece of mRNA that encodes the spike protein of the SARS-CoV-2 virus.

 

moar

https://www.avantorsciences.com/us/en/support/knowledge-center/history-of-mrna-vaccines